EUVIMEDEUVIMED entdecken
Open Access

Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates

Oriana Kreutzfeld iD, Stephen Orena, Martin Okitwi, Patrick K Tumwebaze, Oswald Byaruhanga, Thomas Katairo, Melissa D Conrad iD, Jennifer Legac, Shreeya Garg, Rebecca Crudale, Ozkan Aydemir, David Giesbrecht und 7 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00466-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Oriana Kreutzfeld und 18 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Drug Resistance. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medicines for Malaria Venture (MMV), HHS | NIH | OSC | Common Fund (NIH Common Fund), NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel antimalarials are urgently needed to combat rising resistance to available drugs. The imidazolopiperazine ganaplacide is a promising drug candidate, but decreased susceptibility of laboratory strains has been linked to polymorphisms in the Plasmodium falciparum cyclic amine resistance locus (PfCARL), acetyl-CoA transporter (PfACT), and UDP-galactose transporter (PfUGT). To characterize parasites causing disease in Africa, we assessed ex vivo drug susceptibilities to ganaplacide in 750 P . falciparum isolates collected in Uganda from 2017 to 2023. Drug susceptibilities were assessed using a 72-hour SYBR Green growth inhibition assay. The median IC 50 for ganaplacide was 13.8 nM, but some isolates had up to 31-fold higher IC 50 s (31/750 with IC 50 > 100 nM). To assess genotype-phenotype associations, we sequenced genes potentially mediating altered ganaplacide susceptibility in the isolates using molecular inversion probe and dideoxy sequencing methods. PfCARL was highly polymorphic, with eight mutations present in >5% of isolates. None of these eight mutations had previously been selected in laboratory strains with in vitro drug pressure and none were found to be significantly associated with decreased ganaplacide susceptibility. Mutations in PfACT and PfUGT were found in ≤5% of isolates, except for two frequent (>20%) mutations in PfACT; one mutation in PfACT (I140V) was associated with a modest decrease in susceptibility. Overall, Ugandan P. falciparum isolates were mostly highly susceptible to ganaplacide. Known resistance mediators were polymorphic, but mutations previously selected with in vitro drug pressure were not seen, and mutations identified in the Ugandan isolates were generally not associated with decreased ganaplacide susceptibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsDrug ResistanceUgandaHumansMalaria, FalciparumProtozoan ProteinsInhibitory Concentration 50PiperazinesParasitic Sensitivity Tests

Stichwörter der Autor:innen

PfACTPfCARLPfUGTPlasmodium falciparumantimalarial drugsdrug susceptibilityganaplacidemalaria

Substanzen

AntimalarialsProtozoan ProteinsPiperazines

Autor:innen und Institutionen

  • University of California, San Francisco, California, USA.
  • Infectious Diseases Research Collaboration, Kampala, Uganda.
  • Brown University, Providence, Rhode Island, USA.
  • Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
  • Medicines for Malaria Venture, Geneva, Switzerland.
  • Dominican University of California, San Rafael, California, USA.

ORCID-Profile: Oriana Kreutzfeld, Melissa D Conrad, Roland A Cooper, Philip J Rosenthal

Förderung

  • Medicines for Malaria Venture (MMV)
  • HHS | NIH | OSC | Common Fund (NIH Common Fund)
  • NIAID NIH HHS

Zitieren

APA

Kreutzfeld, O., Orena, S., Okitwi, M., Tumwebaze, P. K., Byaruhanga, O., Katairo, T., Conrad, M. D., Legac, J., Garg, S., Crudale, R., Aydemir, O., Giesbrecht, D., Nsobya, S. L., Blasco, B., Duffey, M., Rouillier, M., Bailey, J. A., Cooper, R. A., & Rosenthal, P. J. (2024). Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00466-24

Vancouver

Kreutzfeld O, Orena S, Okitwi M, Tumwebaze PK, Byaruhanga O, Katairo T, et al. Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00466-24

BibTeX
@article{Kreutzfeld2024,
  author = {Kreutzfeld, Oriana and Orena, Stephen and Okitwi, Martin and Tumwebaze, Patrick K and Byaruhanga, Oswald and Katairo, Thomas and Conrad, Melissa D and Legac, Jennifer and Garg, Shreeya and Crudale, Rebecca and Aydemir, Ozkan and Giesbrecht, David and Nsobya, Samuel L and Blasco, Benjamin and Duffey, Maelle and Rouillier, Melanie and Bailey, Jeffrey A and Cooper, Roland A and Rosenthal, Philip J},
  title = {Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00466-24}
}
Kostenlos starten →